- Report
- August 2025
- 184 Pages
Global
From €3181EUR$3,545USD£2,792GBP
€3535EUR$3,939USD£3,102GBP
- Report
- August 2025
- 197 Pages
Global
From €3181EUR$3,545USD£2,792GBP
€3535EUR$3,939USD£3,102GBP
- Report
- August 2025
- 199 Pages
Global
From €3181EUR$3,545USD£2,792GBP
€3535EUR$3,939USD£3,102GBP
- Report
- August 2025
- 180 Pages
Global
From €3181EUR$3,545USD£2,792GBP
€3535EUR$3,939USD£3,102GBP
- Report
- August 2025
- 182 Pages
Global
From €3181EUR$3,545USD£2,792GBP
€3535EUR$3,939USD£3,102GBP
- Report
- August 2025
- 195 Pages
Global
From €3181EUR$3,545USD£2,792GBP
€3535EUR$3,939USD£3,102GBP
- Report
- August 2025
- 196 Pages
Global
From €3181EUR$3,545USD£2,792GBP
€3535EUR$3,939USD£3,102GBP
- Report
- August 2025
- 185 Pages
Global
From €3181EUR$3,545USD£2,792GBP
€3535EUR$3,939USD£3,102GBP
- Report
- August 2025
- 190 Pages
Global
From €3181EUR$3,545USD£2,792GBP
€3535EUR$3,939USD£3,102GBP
- Report
- August 2025
- 188 Pages
Global
From €3181EUR$3,545USD£2,792GBP
€3535EUR$3,939USD£3,102GBP
- Report
- June 2025
- 200 Pages
Global
From €2234EUR$2,490USD£1,961GBP
- Report
- November 2025
- 307 Pages
Global
From €5249EUR$5,850USD£4,607GBP
- Report
- November 2025
- 392 Pages
Global
From €5249EUR$5,850USD£4,607GBP
- Report
- November 2025
- 174 Pages
Global
From €5249EUR$5,850USD£4,607GBP
- Report
- November 2025
- 196 Pages
Global
From €5249EUR$5,850USD£4,607GBP
- Report
- October 2025
- 250 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- October 2025
- 250 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- October 2025
- 250 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- September 2025
- 250 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- September 2025
- 250 Pages
Global
From €4029EUR$4,490USD£3,536GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more